International Journal of High Dilution Research - ISSN 1982-6206 <div style="width: 100%; text-align: justify; font-size: 12px;">IJHDR is a full submission free / open-access electronic journal (diamond type) specialized in the multidisciplinary High Dilution (HD) research field. Hosted by GIRI ( and supported by HRI (, HD Science (, and ECH (, IJHDR works in a double-blinded peer-reviewed system, counting on an international editorial board. From June 2022, the annual periodicity was set to a continuous flow system.</div> <div style="width: 100%; text-align: justify; font-size: 12px;"> </div> <div style="width: 100%; text-align: justify; font-size: 12px;">The journal is listed at:</div> <div style="width: 100%; text-align: justify; font-size: 12px;">Diadorim (<em>Diretório de políticas editoriais das revistas científicas brasileiras</em>)<br />LILACS (<em>Literatura Latino-Americana e do Caribe em Ciências da Saúde</em> - BIREME/PAHO/WHO)<br />Latindex-Directory<br />Miguilim (Directory of Brazilian Electronic Scientific Journals)<br />Scopus<br />EBSCO<br />Qualis-Periódicos CAPES - Brazil</div> <div style="width: 100%; text-align: justify; font-size: 12px;"><strong>Other lists:</strong> OJS/PKP, Google Scholar, DOAJ, NSDL/NSF, Open J-Gate, JournalSeek, Scopus, Scimago (H index = 9 in 2021), and BVS.</div> <div style="width: 100%; text-align: justify; font-size: 12px;"> </div> <div style="width: 100%; text-align: justify; font-size: 12px;">IJHDR also counts on the services of ABEC and Crossref. Eventual plagiarism is checked by the iThenticate service.</div> <div style="width: 100%; text-align: justify; font-size: 12px;">IJHDR adopts the ethical standards described by the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE). </div> <div style="width: 100%; text-align: justify; font-size: 12px;"><strong>The average time between submission and publication is 6 - 8 months.</strong></div> <div style="width: 100%; text-align: justify; font-size: 12px;"> <p>Since August 2021, IJHDR has adopted the Creative-Commons license: <strong><span class="cc-license-title">Attribution-NonCommercial-ShareAlike 4.0 International</span> <span class="cc-license-identifier">(CC BY-NC-SA 4.0).</span></strong></p> </div> en-US <p>&lt;a rel="license" href=""&gt;&lt;img alt="Creative Commons License" style="border-width:0" src="" /&gt;&lt;/a&gt;&lt;br /&gt;This work is licensed under a &lt;a rel="license" href=""&gt;Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License&lt;/a&gt;.</p> [email protected] (Prof. Leoni Villano Bonamin) [email protected] (Leoni Villano Bonamin) Tue, 20 Feb 2024 01:05:58 +0000 OJS 60 Utility of Kent's Repertory in the treatment of candidiasis: An open labelled, Single arm, interventional clinical trial <p><strong>ABSTRACT</strong></p> <p><strong>Background: </strong>Candidiasis is the most significant opportunistic infection impacting the Quality of life. <strong>Objective: </strong>This study assess the effectiveness of individualized homoeopathy (IH) in centesimal scale selected from the Kent’s repertory in cases of Candidiasis. <strong>Methods: </strong>This is open – label, prospective, Single-arm, non-randomized, non-controlled clinical trial of pre-post comparison design was conducted at the Repertory outpatient department (OPD) of National Institute of Homoeopathy, Kolkata, India. <strong>Result: </strong>Calculated t<sub>29</sub> value is 8.04 OR 9.17 by using NRS and MCAQ scoring scale and on referring t-table at degree of freedom 29,&nbsp; it is found that the t-value is 2.05 at p=0.05. However our calculated value 8.04 or 9.17 is &gt; 2.05 (t at p=0.05). As the calculated t-value is greater than the table value at <strong>α &nbsp;</strong>= 0.05 . So the result is significant at p ≤ 0.05. There is statically significant improvement in pre and post intervention status of patients enrolled in this clinical study. <strong>Conclusion: </strong>This study provides a positive trend to support the effect of IH (Individualized Homoeopathy) selected on the basis of principal of Kent’s repertory&nbsp; in patients with different variety of candidiasis and warrants further evaluation in RCT (Randomized control trial) with higher sample size.</p> Nitin Kumar Saklani, Ramkripal Prajapati Copyright (c) 2024 Nitin Kumar Saklani, Ramkripal Prajapati Thu, 14 Mar 2024 00:00:00 +0000 Case report: use of conium maculatum as an aid to lower limb pain and paresia in type 1 neurofibromatosis in treatment of optic pathway glioma <p>Neurofibromatosis type 1 is one of the most common autosomal dominant disorders, presenting a higher risk of developing plexiform tumors and neurofibromas, whose conventional treatment, based on surgical, chemotherapy or radiotherapy procedures, still has limitations. Comorbidities such as neuralgic, muscular or paretic and paralytic pain may occur depending on the tumor situation or the plexiform neurofibroma. Given the difficult approach to these patients, and with the aim of expanding research and homeopathic knowledge about these cases, we present a case of pain associated with lumbosacral plexiform neurofibroma during oncological treatment for Glioma of the Optic Pathways, without surgical indication, but with difficult pain. control, even when using analgesics and antidepressants. Chemotherapy oncological treatment, due to crises and maintenance of pain, had been postponed. As an aid in controlling the symptoms, considering the ascending paretic pain syndrome of the left lower limb, the homeopathic medicine Conium maculatum was used as a complementary aid to the therapy. The patient's symptoms improved and she was able to continue with the chemotherapy treatment indicated, with a progressive reduction in the use of analgesics until they were discontinued.</p> Bruno Coutinho de Oliveira Copyright (c) 2024 Bruno Coutinho de Oliveira Mon, 01 Apr 2024 00:00:00 +0000 A Randomized, Placebo-controlled Homeopathic Drug-proving of SARS CoV-2 nosode (BiosimCovex) in healthy volunteers <p><strong>Introduction</strong></p> <p>The Homeopathic Pathogenetic Trial (HPT, Drug-proving) is a systematic examination and recording of the symptoms experienced by healthy volunteers after an administration of an investigational medicinal substance. Randomized, placebo-controlled HPT was conducted using BiosimCovex (SARS CoV-2 nosode) in healthy volunteers.&nbsp;</p> <p><strong>Materials and methods</strong></p> <p>BiosimCovex 30c was given orally in a randomized, placebo-controlled trial to examine the safety and pathogenetic effects of 30 volunteers (18- 65 years of age and both genders). Volunteers were administered a dose of 6 pills of the nosode once a day for two weeks followed by 30 days observation period. Pre and post-examination (physical), vital signs, and laboratory investigations were done with a run-in period of 7 days. Symptoms experienced by the volunteers were recorded and analyzed, and Qualitative and Quantitative indices per volunteer were reported. Trial registered at (CTRI/2022/06/043392).</p> <p><strong>Results</strong></p> <p>BiosimCovex nosode exhibited quantitatively distinct symptoms, which can be applied in clinical practice. The number of symptoms reported in the verum arm was 73 (placebo 11). The incidence of the Pathogenetic effect per volunteer in the verum group was 8.1 vs that of the placebo 5.5. The Qualitative Pathogenetic Index was 0.295 in the verum group as compared to the placebo 0.193. The symptoms observed matched with the symptoms produced in an open-label Phase 1 study conducted during the COVID-19 pandemic and also with that of the viral infection. There were no serious/fatal adverse events during the study. Safe use was documented.</p> <p><strong>Conclusion</strong></p> <p>BiosimCovex nosode developed during a pandemic condition produced specific symptoms in the homeopathic pathogenetic trial which could be used in clinical practice.</p> Rajesh Shah, Ms Copyright (c) 2024 Rajesh Shah, Ms Mon, 01 Apr 2024 00:00:00 +0000 Repurposing the anti-angiogenic activity of homoeopathic medicines by employing Chick embryo model- An In-Ovo Study <p><strong>Background</strong>: Homoeopathic medicines have the potential in treatment of patients suffering from cancers, Diabetic Retinopathy, and hemorrhagic disorders wherein anti- angiogenesis plays a vital role. Homoeopathic medicines have been used to treat haemorrhagic disorders. For example, Hamamelis is used in haemorrhages, varicose veins and in venous congestion. Thalaspi bursa is used in flabby condition of uterus, haemorrhagic conditions of uterine fibroid. This been said, their mechanism of action remains unknown. Therefore, this study was intended to establish angiogenic/anti-angiogenic effect of the selected homoeopathic medicines employing chick embryo model.</p> <p><strong>Objective:</strong></p> <ol> <li>To study the anti-angiogenic properties of selected homoeopathic medicines employing YSM assay in the chick embryo model.</li> <li>To test the toxicity of selected homoeopathic medicines through Chick embryo model.</li> </ol> <p><strong>Materials and Method</strong>: Yolk Sac Membrane is widely utilized as an in vivo system to study angiogenesis and anti-angiogenesis. The images for all YSMs were captured and were analyzed for angiogenic/anti-angiogenic effect.</p> <p><strong>Results:</strong> Significant anti-angiogenic effects were observed in 10% concentrations of Hamamelis200cH, Thalaspi bursa 200cH and Thalaspi bursa 1M. Reduction of vessel density and total vessel network length, total branching points, total nets and total segment symbolizes that these medicines have anti-angiogenic potential and so they help in treating menstrual disorders, which is followed with cramps and discharge of clots.</p> <p><strong>Conclusion:</strong> The mechanism of action of selected homoeopathic medicines as anti- angiogenic agent is proved which can be used to combat various diseases like haemorrhages, varicose veins, in venous congestion and problems related to haemorrhagic disorders. This will further help to study the action of these Homoeopathic medicines as potential line of treatment in patients suffering from cancers, Diabetic Retinopathy, hemorrhagic disorders wherein anti- angiogenesis plays a vital role.</p> Parth Aphale, Chinmay Gawade, Dharmendra Sharma, Dr. Ramesh Bhonde, Dr. Avinash Sanap Copyright (c) 2024 DR PARTH APHALE, Chinmay Gawade, Dharmendra Sharma, Dr. Ramesh Bhonde, Dr. Avinash Sanap Mon, 01 Apr 2024 00:00:00 +0000 Efficacy of Homoeopathic Ultra High Dilutions in management of Dysmenorrhoea: A Review <p><strong>Introduction:</strong> Dysmenorrhea, or painful menstruation, affects a substantial portion of women worldwide, with prevalence rates reaching up to 67 to 90% among young women. This condition, characterized by intense lower abdominal cramps and associated symptoms, has a significant impact on women's quality of life. Conventional treatments like non-steroidal anti-inflammatory drugs (NSAIDs) have limitations, leading many to explore alternative therapies such as homeopathy. <strong>Objective:</strong> This article reviews the effects of homeopathic treatments on dysmenorrhea patients and examines seven studies conducted in this context. <strong>Methods:</strong> Studies which meet the specific required criteria; involving dysmenorrhea and Homoeopathy and being published in peer-reviewed English-language scientific journals were only included. Various parameters, such as disease intensity scales, the Menstrual Distress Questionnaire (MDQ), Pain Rating Scale (PRS), Visual Analogue Scale (VAS), and quality of life (QoL) using the World Health Organization Quality of Life: Brief Version (WHOQOL-BREF) scale, numerical rating scale (NRS), and verbal multidimensional scoring system (VMSS), were evaluated. The results before and after treatment with homoeopathic high dilutions have been compared and summarized. <strong>Results:</strong> Clinical analysis and statistical data of reviewed studies reveal homeopathic high dilutions as effective for Primary Dysmenorrhea, reducing pain (VAS), improving quality of life (WHOQOL), and demonstrating safety, emphasizing their holistic potential.</p> <p>&nbsp;</p> DR PARTH APHALE, Dr. Dharmendra Sharma, Himanshu Shekhar Copyright (c) 2024 DR PARTH APHALE, Dr. Dharmendra Sharma, Himanshu Shekhar Fri, 08 Mar 2024 00:00:00 +0000 The Crucial Role of Prognostic Factor Research Models in Guiding Homeopathic Prescriptions: An Evidence Based Medicine perspective. Aditya Dilipkumar Patil, Sargam Ramesh Singh Copyright (c) 2024 Aditya Dilipkumar Patil, Sargam Ramesh Singh Mon, 01 Apr 2024 00:00:00 +0000